Semaglutide is a GLP-1 receptor agonist FDA-approved for weight management and type 2 diabetes. It is one of the most widely studied and prescribed incretin therapies. This page is educational only.
| Type | GLP-1 receptor agonist |
|---|---|
| Targets | GLP-1 receptor |
| Half-life | ~7 days |
| Administration | Subcutaneous injection (weekly) or oral |
| Primary research focus | Weight management and type 2 diabetes |
| Status | FDA-approved (Ozempic, Wegovy, Rybelsus) |
Semaglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a hormone produced in the gut that plays a central role in glucose metabolism and appetite regulation. Developed by Novo Nordisk, it was engineered with structural modifications that extend its duration of action to approximately one week, making it suitable for once-weekly injection. It belongs to the broader class of GLP receptor agonists and is one of the most extensively studied compounds in the incretin therapy space.
Semaglutide is marketed under several brand names: Ozempic for type 2 diabetes management, Wegovy for chronic weight management in adults with obesity, and Rybelsus as the first oral GLP-1 receptor agonist approved for type 2 diabetes. Its dual-indication profile and robust clinical trial program have made it a cornerstone of modern metabolic medicine.
For a focused overview of semaglutide as a peptide compound, including amino acid structure and classification, see the semaglutide peptide profile.
Semaglutide mimics native GLP-1 by binding to and activating GLP-1 receptors expressed in the pancreas, brain, and gastrointestinal tract. In the pancreas, this promotes glucose-dependent insulin secretion and suppresses glucagon release, improving glycemic control. In the hypothalamus, GLP-1 receptor activation reduces appetite and food intake by modulating satiety signaling pathways. Semaglutide also slows gastric emptying, contributing to reduced caloric absorption and increased post-meal fullness.
The long half-life of approximately seven days is achieved through two key modifications: a fatty acid chain that enables strong non-covalent binding to serum albumin, and amino acid substitutions that confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Albumin binding slows renal clearance and creates a circulating reservoir of the drug. These properties allow once-weekly subcutaneous dosing at steady state, with the oral formulation (Rybelsus) using an absorption enhancer (SNAC) to enable daily gastrointestinal uptake.
Semaglutide's efficacy has been established through the large-scale STEP (Semaglutide Treatment Effect in People with Obesity) and SUSTAIN trial programs, along with landmark cardiovascular outcome studies.
| Study | Duration | Key Outcome |
|---|---|---|
| STEP 1 | 68 weeks | ~15% mean weight loss vs placebo |
| STEP 2 | 68 weeks | Significant weight loss + HbA1c reduction in T2D |
| STEP 3 | 68 weeks | Enhanced weight loss with intensive lifestyle intervention |
| STEP 5 | 104 weeks | Sustained weight management over 2 years |
| SELECT | 3+ years | 20% reduction in major adverse cardiovascular events |
Individual responses vary based on dosage, adherence, diet, and baseline characteristics. The following timeline reflects commonly reported patterns from clinical trials and real-world use.
| Timeframe | Commonly Reported Effects |
|---|---|
| Week 1–4 | Appetite changes begin; mild nausea is common during initiation |
| Week 4–8 | Dose escalation period; appetite reduction becomes more pronounced |
| Week 8–16 | Noticeable weight loss as therapeutic doses are reached |
| Week 16–28 | Significant weight reduction; most patients on maintenance dose |
| Week 28–52 | Weight loss rate slows as body approaches new equilibrium |
| Week 52+ | Long-term weight maintenance; continued metabolic benefits |
For a detailed week-by-week breakdown, see the Semaglutide Results Timeline Guide.
| Peptide | Receptors | Status | Key Difference |
|---|---|---|---|
| Semaglutide | GLP-1 | FDA-approved | Single target, most real-world evidence |
| Tirzepatide | GLP-1 + GIP | FDA-approved | Dual target, greater weight loss in trials |
| Retatrutide | GLP-1 + GIP + Glucagon | Investigational | Triple target, highest trial weight loss |
Explore educational protocol references related to semaglutide and GLP-1 agonist research.